{"entity":{"id":"jedd-wolchok","kind":"person","name":"Jedd D. Wolchok","aka":[],"tldr":"Led CheckMate 067, the trial whose ten-year data showed half of advanced melanoma patients on nivolumab plus ipilimumab are alive.","summary":"Jedd Wolchok (Weill Cornell Medicine; formerly MSKCC) was principal investigator of CheckMate 067, which established nivolumab plus ipilimumab as the most durable therapy in advanced melanoma with median survival beyond six years and ten-year melanoma-specific survival near 50%. He led early ipilimumab development, defined the immune-related response criteria, and co-founded the Parker Institute network. His laboratory studies mechanisms of checkpoint blockade.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolchok%20JD%5BAuthor%5D%20melanoma%20ipilimumab%20nivolumab"}],"tags":["melanoma","immunotherapy","trialist"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pd1","ctla4"],"drugs":["nivolumab","ipilimumab"],"companies":[],"institutions":["weill-cornell-meyer-cancer-center"],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":[],"bottlenecks":[],"keyPapers":["paper-checkmate-067-10-year-nejm-2025","paper-hodi-ipilimumab-melanoma-nejm-2010"],"journals":[],"dependsOn":[],"notes":[],"role":"Meyer Director, Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","institutionId":"weill-cornell-meyer-cancer-center","specialisms":["Melanoma immunotherapy","Checkpoint inhibitor combinations","Immune-related response criteria","Tumour immunology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Wolchok%20JD%5BAuthor%5D%20melanoma%20ipilimumab%20nivolumab"}],"papers":[{"title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma (CheckMate 067)","journal":"NEJM","year":2015,"doi":"10.1056/NEJMoa1504030"},{"title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","journal":"JCO","year":2022,"doi":"10.1200/JCO.21.02229"},{"title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","journal":"Clinical Cancer Research","year":2009,"doi":"10.1158/1078-0432.CCR-09-1624"},{"title":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","journal":"Science","year":2018,"url":"https://doi.org/10.1126/science.aar4060","doi":"10.1126/science.aar4060"},{"title":"CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate%20067%2010-year%20nivolumab%20ipilimumab%20melanoma%20Wolchok%20NEJM%202025"},{"title":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","journal":"New England Journal of Medicine","year":2010,"url":"https://doi.org/10.1056/NEJMoa1003466","doi":"10.1056/NEJMoa1003466"},{"title":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","journal":"New England Journal of Medicine","year":2025,"url":"https://doi.org/10.1056/NEJMoa2407417","doi":"10.1056/NEJMoa2407417"}],"orcid":"0000-0001-6718-2222"},"route":"/people/jedd-wolchok/","neighbours":{"cancer":[{"id":"advanced-melanoma","kind":"cancer","name":"Advanced melanoma (unresectable stage III and stage IV)","route":"/cancers/advanced-melanoma/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"ctla4","kind":"target","name":"CTLA-4","route":"/targets/ctla4/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"institution":[{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","route":"/institutions/parker-institute/"},{"id":"weill-cornell-meyer-cancer-center","kind":"institution","name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","route":"/institutions/weill-cornell-meyer-cancer-center/"}],"trial":[{"id":"checkmate-067","kind":"trial","name":"CheckMate 067","route":"/trials/checkmate-067/"}],"paper":[{"id":"paper-checkmate-067-10-year-nejm-2025","kind":"paper","name":"CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma","route":"/key-papers/paper-checkmate-067-10-year-nejm-2025/"},{"id":"paper-hodi-ipilimumab-melanoma-nejm-2010","kind":"paper","name":"Hodi 2010: ipilimumab, the first checkpoint inhibitor, extends survival in metastatic melanoma","route":"/key-papers/paper-hodi-ipilimumab-melanoma-nejm-2010/"},{"id":"paper-ribas-wolchok-checkpoint-blockade-science-2018","kind":"paper","name":"Ribas and Wolchok 2018: cancer immunotherapy using checkpoint blockade","route":"/key-papers/paper-ribas-wolchok-checkpoint-blockade-science-2018/"}]}}